Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: Relationship to sleep architecture

Psychiatry Research

Volumn 78, Issue 3, 1998, Pages 141-150

  Nishino, Seiji ^a   Mignot, Emmanuel ^a   Benson, Kathleen L ^b   Zarcone Jr , Vincent P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Polysomnography; Psychoendocrinoiogy; Slow wave sleep

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MALE; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SLEEP DISORDER; SLEEP STAGE; SLOW WAVE SLEEP;

ADULT; CORTICOTROPIN-RELEASING HORMONE; DINOPROST; DINOPROSTONE; HUMANS; MALE; PROSTAGLANDIN D2; PROSTAGLANDINS; SCHIZOPHRENIA; SLEEP; SLEEP DISORDERS;

EID: 0032496093     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00012-2     Document Type: Article

References (50)

1. Banki C.M., Bissette G., Arató M., O'Connor L., Nemeroff C.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. American Journal of Psychiatry. 144:1987;873-877.
2. Benson K.L., Faull K.F., Zarcone V.P. Evidence for the role of serotonin in the regulation of slow wave sleep in schizophrenia. Sleep. 14:1991;133-139.
3. Benson K.L., Zarcone V.P. Rapid eye movement sleep eye movements in schizophrenia and depression. Archives of General Psychiatry. 50:1993;474-482.
4. Carroll B.J. Dexamethasone suppression test: a review of contemporary confusion. Journal of Clinical Psychiatry. 46:1985;13-24.
5. Carroll B.J., Feinberg M., Greden J.F.et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Archives of General Psychiatry. 38:1981;837-853.
6. Dore-Duffy P., Ho S.Y., Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology. 41:1991;322-324.
7. Eguchi N., Hayashi H., Urade Y., Ito S., Hayaishi O. Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. Journal of Pharmacology and Experimental Therapy. 247:1988;671-679.
8. Ehlers C.L., Reed T.K., Henriksen S.J. Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. Neuroendocrinology. 42:1986;467-474.
9. Feinberg I., Braum N., Koresko R.L., Gottlieb F. Stage 4 sleep in schizophrenia. Archives of General Psychiatry. 21:1969;262-266.
10. Feinberg I., Koresko R.L., Heller N., Steinberg H.R. Unusually high dream time in hallucinating patient. American Journal of Psychiatry. 121:1965;1018-1020.
11. Feldberg W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis. Psychological Medicine. 6:1976;359-369.
12. Gerner R.H., Merrill J.E. Cerebrospinal fluid prostaglandin E in depression, mania, and schizophrenia compared to normals. Biological Psychiatry. 18:1983;565-569.
13. Giles H., Leff P. The biology and pharmacology of PGD2. Prostaglandins. 35:1988;277-300.
14. 2. FASEB Journal. 5:1991;2575-2581.
15. 2 in human urine. Journal of Biological Chemistry. 263:1988;16619-16625.
16. Hoffmann A., Conradt H.S., Gross G., Nimtz M., Lottspeich F., Wurster U. Purification and chemical characterization of β-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. Journal of Neurochemistry. 61:1993;451-456.
17. Horrobin D.F. Schizophrenia as a prostaglandin deficiency. Lancet. 1:1977;936-937.
18. Horrobin D.F., Ally A.I., Karmali R.A., Karmazyn M., Manku M.S., Morgan R.O. Prostaglandins and schizophrenia: further discussion of the evidence. Psychological Medicine. 8:1978;43-48.
19. Krueger J.M., Takahashi S., Kapas L. Cytokines in sleep regulation. Advances in Neuroimmunology. 5:1995;171-188.
20. Kupfer D.J., Wyatt R.J., Scott J., Snyder F. Sleep disturbance in acute schizophrenic patients. American Journal of Psychiatry. 126:1970;1213-1223.
21. Linnoila M., Whorton R., Rubinow D.R., Cowdry R.W., Ninan P.T., Waters R.N. CSF prostaglandin levels in depressed and schizophrenic patients. Archives of General Psychiatry. 40:1983;405-406.
22. Mathé A.A., Wiesel F.A., Sedvall G., Nybäck H. Increased content of immunoreactive prostaglandin E in cerebrospinal fluid of patients with schizophrenia. Lancet. 1(8158):1980;16-18.
23. 2 is involved in physiological sleep-wake regulation in rats. Proceedings of the National Academy of Sciences USA. 86:1989;5666-5669.
24. Matsumura H., Nakajiima T., Osaka T.et al. Prostaglandin D2-sensitive, sleep-promoting zone defined in the ventral surface of the rostral basal forebrain. Proceedings of the National Academy of Sciences USA. 91:1994;11998-20002.
25. Morrow J.D., Guzzo C., Lazarus G., Oates J.A., Roberts L.J. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. Journal of Investigative Dermatology. 1995:1995;6.
26. Nemeroff C.B., Widerlov E., Bissette G.et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
27. Nishino S., Mignot E., Kilduff T.et al. Prostaglandin E2 levels in cerebrospinal fluid of normal and narcoleptic dogs. Biological Psychiatry. 28:1990;904-910.
28. Obal, F., Opp, M., Sary, G., Krueger, J.M., 1990. Endocrine mechanisms in sleep regulation. In: Inoue, S., Krueger, J.M. (Eds.), Endogenous Sleep Factors. SPB Academic Publishing, The Hague, pp. 109-120.
29. Opp M., Obal F., Krueger J.M. Corticotropin-releasing factor attenuates interleukin 1-induced sleep and fever in rabbits. American Journal of Physiology. 257:1989;R528-R535.
30. Pentreath W., Rees K., Owolabi K., Philip K.A., Doua F. The somnogenic T lymphocyte suppressor prostaglandin D2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients. Transactions of the Royal Society of Tropical Medicine and Hygiene. 84:1990;795-799.
31. Raadsheer F.C., Oorschot D.E., Verwer R.W.H., Tilders F.J.H., Swaab D.F. Age-related increase in the total number of corticotropin-releasing hormone neurons in the human paraventricular nucleus in controls and Alzheimer's Disease: comparison of the disector with an unfolding method. Journal of Comparative Neurology. 339:1994;447-457.
32. Rechtschaffen, A., Kales, A., 1968. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects. Superintendent of Documents, U.S. Government Printing Office, Washington, DC.
33. Reich L., Weiss B.L., Coble P. Sleep disturbance in schizophrenia. Archives of General Psychiatry. 32:1975;51-55.
34. Romero S.D., Chyatte D.C., Byer D.E., Romero J.C., Yaksh T.L. Measurement of prostaglandins in the cerebrospinal fluid in cat, dog, and man. Journal of Neurochemistry. 43:1984;1642-1649.
35. Roy A., Pickar D., Paul S., Doran A., Chrousos G., Gold P. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. American Journal of Psychiatry. 144:1987;641-645.
36. Schürmeyer T.H., Avgerinos P.C., Gold P.W.et al. Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. Clinical Endocrinology and Metabolism. 59:1984;1103-1108.
37. Shimizu T., Wolfe L.S. Short review: arachidonic acid cascade and signal transduction. Journal of Neurochemistry. 55:1990;1-15.
38. Spitzer, R.L., Endicott, J., 1977. Schedule for Affective Disorders and Schizophrenia (SADS), 3rd ed. New York State Psychiatric Institute, New York.
39. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry. 35:1978;773-782.
40. Stern M., Fram D., Wyatt R. All night sleep studies of acute schizophrenics. Archives of General Psychiatry. 20:1969;470-477.
41. Tandon R., Lewis C., Taylor S.F.et al. Relationship between DST nonsuppression and shortened REM latency in schizophrenia. Biological Psychiatry. 40:1996;660-663.
42. Tandon R., Mazzara C., DeQuardo J.R., Craig K.A. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement and outcome. Biological Psychiatry. 29:1991;953-964.
43. Traub A.C. Sleep stage deficits in chronic schizophrenia. Psychological Reports. 31:1972;815-820.
44. Tsai C.Y., Wu T.H., Tsai S.T.et al. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scandinavian Journal of Rheumatology. 23:1994;57-63.
45. Ueno, R., Hayaishi, O., Osama, H. et al., 1985. Prostaglandin D2 regulates physiological sleep. In: Inoue, S., Borbély, A. (Eds.), Endogenous Sleep Substances and Sleep Regulation. Japanese Scientific Societies Press, Tokyo, pp. 193-201.
46. Urade Y., Kitahama K., Ohishi H., Kaneko T., Mizuno N., Hayaishi O. Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Proceedings of the National Academy of Sciences USA. 90:1993;9070-9074.
47. Weiner M.F., Davis B.M., Mohs R.C., Davis K.L. Influence of age and relative weight on cortisol suppression in normal subjects. American Journal of Psychiatry. 144:1987;646-649.
48. Yergey J.A., Karanian J.W., Salem N., Heyes M.P., Ravitz B., Linnoila M. Prostaglandins in cerebrospinal fluid of healthy human volunteers, abstinent alcoholics and rhesus monkeys. Prostaglandins. 37:1989;505-517.
49. Zarcone, V.P., Benson, K.L., 1994. Sleep and schizophrenia. In: Kryger, M.H., Roth, T., Dement, W.C. (Eds.), Principles and Practice of Sleep Medicine, 2nd ed. WB Saunders, London, pp. 914-926.
50. Zarcone V.P., Benson K.L., Berger P.A. Abnormal rapid eye movement latencies in schizophrenia. Archives of General Psychiatry. 44:1987;45-48.